越南慢性乙型肝炎感染者治疗资格评估与简化标准
在越南400例初治慢性HBV感染者中,42%符合国家指南治疗标准。简化的TREAT-B评分选择治疗资格表现良好(AUROC 0.89),在89例有2次ALT测量者中显著优于简化WHO标准(P < .001)。TREAT-B是无需HBV DNA和FibroScan的更好替代方案。
要点
- 越南慢性HBV感染者中42%符合抗病毒治疗标准。
- TREAT-B评分选择治疗资格AUROC 0.89,敏感性74.3%,特异性88.4%。
- 在89例有2次ALT测量者中TREAT-B显著优于简化WHO标准。
核心结论
- 越南较大比例慢性HBV感染者需要抗病毒治疗。
- TREAT-B是无需HBV DNA和FibroScan指示治疗资格的更好替代方案,可能有助于扩大治疗干预。
研究设计与样本
- 来自越南HBV感染患者队列,分析400例连续初治HBV单一感染患者。
- 以国家指南(基于HBV DNA定量和FibroScan)为参考,评估治疗资格比例及简化标准(TREAT-B评分和简化WHO标准)的准确性。
主要发现
- 400例中49%男性,中位年龄38岁(范围18-86),32% HBeAg阳性,中位HBV DNA 4.8 log10 IU/mL(检测不到至8.4),中位FibroScan 5.3 kPa(3.0-67.8)。
- 25%有显著肝纤维化,包括12%肝硬化。
- 167例(42%)符合国家指南治疗标准。
- TREAT-B选择治疗资格AUROC 0.89(95%CI 0.87-0.92),敏感性74.3%,特异性88.4%。
- 在89例有6个月内2次ALT测量者中,TREAT-B的AUROC显著高于简化WHO标准(P < .001)。
关键数值与推荐
- 国家指南治疗标准:基于HBV DNA定量和FibroScan,42%患者符合。
- TREAT-B评分:AUROC 0.89(95%CI 0.87-0.92),敏感性74.3%,特异性88.4%。
- 在89例有2次ALT测量者中,TREAT-B的AUROC显著高于简化WHO标准(P < .001)。
临床怎么用
- 在缺乏HBV DNA和FibroScan的资源有限地区,可考虑用TREAT-B评分指示治疗资格。
- TREAT-B可能有助于扩大越南慢性HBV感染的治疗干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment eligibility and the accuracy of its simplified criteria have been poorly documented in patients with chronic hepatitis B virus (HBV) infection worldwide, especially in low- and middle-income countries. METHODS: From a cohort of HBV-infected patients in Vietnam, we assessed the proportion of patients eligible for treatment using the national guidelines based on reference tests (HBV DNA quantification and FibroScan); and the accuracy of simplified treatment criteria free from HBV DNA and FibroScan (Treatment Eligibility in Africa for the Hepatitis B Virus [TREAT-B] score and simplified World Health Organization [WHO] criteria) to select patients for antiviral therapy using the national guidelines as a reference. RESULTS: We analyzed 400 consecutive treatment-naïve HBV-monoinfected patients: 49% males, median age 38 years (range, 18-86), 32% hepatitis B e antigen-positive, median HBV DNA 4.8 log10 IU/mL (undetectable -8.4), median FibroScan 5.3 kPa (3.0-67.8), and 25% having significant liver fibrosis including 12% with cirrhosis. Of these, 167 (42%) fulfilled treatment criteria according to national guidelines. Using the national criteria as a reference, the performance of TREAT-B to select patients for treatment was high (area under the receiver operating characteristic [AUROC], 0.89 [95% confidence interval 0.87-0.92]) with a sensitivity of 74.3% and a specificity of 88.4%. In a subset of patients with 2 alanine aminotransferase measurements over a 6-month period (n = 89), the AUROC of TREAT-B was significantly higher than that of the simplified WHO criteria (P < .001). CONCLUSIONS: Our study suggests that a large proportion of patients with chronic HBV infection require antiviral therapy in Vietnam. Compared with the simplified WHO criteria free from HBV DNA quantification, TREAT-B is a better alternative to easily indicate treatment eligibility and might help scale up treatment intervention in Vietnam.
引用
- Vu Hai V, Shimakawa Y, Kim J, et al. Assessment and Simplification of Treatment Eligibility Among Patients With Chronic Hepatitis B Infection in Vietnam. Clin Infect Dis. 2021. PMID: 33331880. doi:10.1093/cid/ciaa1814
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。